Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danirixin in mild to moderate COPD
NCT03170232Phase 2Terminated
- Sponsor
- GSK
- Start
- Oct 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of danirixin in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Oct 2017; status: terminated.
02
Drugs
danirixin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03170232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03170232.